Google Übersetzer
Nektar Therapeutics
About
Nektar Therapeutics (NASDAQ:NKTR) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Apr 21 2026
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
Apr 20 2026
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
Apr 19 2026
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
Mar 28 2026
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Recent Videos
STRONG RECOVERY | NKTR STOCK ANALYSIS | NEKTAR THERAPEUTICS STOCK
Apr 25, 2026
Nektar Therapeutics 52-Week Topline Results from REZOLVE-AA Phase 2b Study of Rezpegaldesleukin
Apr 21, 2026
🧬 What If You Could RETRAIN Your Immune System To Stop Attacking You? 🤯💊
Apr 21, 2026
NKTR, Nektar Therapeutics, 2026-04-20, stock prices dynamics, stock of the day
Apr 21, 2026
Financials
Revenue
$55.23 M
Market Cap
$2.21 B
EPS
-9.73